Toppan Holdings has established a new company, Toppan Global Medical Healthcare, in Houston, Texas, to advance its personalized cancer medicine and drug discovery support businesses.
By establishing a base in Helix Park’s TMC3 Collaborative Building, a commercial life sciences and innovation hub within the Texas Medical Center, the company gains direct access to TMC’s dense network of cancer research, clinical facilities, and patient populations. Toppan Holdings aims to accelerate research and development and support the real-world implementation of personalized cancer medicine using its proprietary invivoid 3D cell culture technology.
In modern cancer treatment, there is a rapidly growing global demand for “personalized medicine,” which selects the most effective therapies and drugs for each individual patient. In July 2025, Toppan Holdings entered into a strategic alliance with The University of Texas MD Anderson Cancer Center to co-develop clinical tools that evaluate treatment efficacy using patient-derived samples.
The newly established company will serve as a strategic headquarters to directly manage collaborations with local medical institutions and pharmaceutical companies in the United States, the world’s largest healthcare market.
Toppan Global Medical Healthcare will focus on the following key areas:
Acceleration of clinical validation: Deepen joint research with UT MD Anderson to expedite clinical validation studies across several cancer types and work toward obtaining College of American Pathologists (CAP)/Clinical Laboratory Improvement Amendments (CLIA) certification.
Expansion of drug discovery support: Contribute to accelerating and enhancing new drug development by providing major U.S. pharmaceutical companies with an efficient drug screening environment utilizing invivoid.
Establishment of a global network: Leverage Houston’s position as a hub of medical innovation to incorporate cutting-edge knowledge, top-tier talent, and connections with research institutions into global business development.
Through Toppan Global Medical Healthcare, Toppan Holdings will build a track record of clinical success in the United States and contribute to a society where optimal medical care is delivered to every cancer patient. Toppan Holdings has positioned the medical and healthcare field as a core pillar of growth and will continue to aggressively expand its business on a global scale.
Invivoid is Toppan Holdings’ proprietary 3D cell culture technology, developed through joint research with the University of Osaka. It enables the simple and rapid creation of artificial tissues that closely mimic living organisms.
